No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan

CPT-11 (irinotecan) is a DNA-topoisomerase I inhibitor with preclinical activity against neuroblastoma (NB) xenografts. The aim was to establish in vivo an NB xenograft resistant to CPT-11 in order to study the resistance mechanisms acquired in a therapeutic setting. IGR-NB8 is an immature NB xenogr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Calvet, L, Santos, A, Valent, A, Terrier-Lacombe, M-J, Opolon, P, Merlin, J-L, Aubert, G, Morizet, J, Schellens, J H M, Bénard, J, Vassal, G
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2004
Assuntos:
Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2747712/
https://ncbi.nlm.nih.gov/pubmed/15292932
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602079
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados